HMOCC-1, a human monoclonal antibody that inhibits adhesion of ovarian cancer cells to human mesothelial cells
HMOCC-1, a human monoclonal antibody that inhibits adhesion of ovarian cancer cells to human mesothelial cells
复制标题
DOI：
10.1016/j.ygyno.2004.06.024
复制
发表时间：
2004-11-01
影响因子：
4.7
通讯作者：
Nozawa, S
中科院分区：
文献类型：
--
作者：
Suzuki, N;Aoki, D;Nozawa, S
目标。卵巢癌是最常见的妇科癌症之一，由于目前的治疗方法在实现和维持缓解方面不够有效，因此预后最差。为了开发新的治疗方法，在 KM 小鼠中培养了一种识别人卵巢癌细胞的单克隆抗体。方法。利用 KM 小鼠骨髓瘤细胞和脾细胞的杂交瘤建立了针对 RMG-I（卵巢癌细胞系）的人单克隆抗体。研究了各种类型卵巢癌和其他肿瘤的免疫组织化学反应性。 RMG-I 细胞用 N-糖苷酶 F、NaOH、H2SO4 和 Gal NAC-α-benzyl 处理，通过蛋白质印迹研究靶抗原。还研究了 HMOCC-1 对 RMG-I 细胞与培养的人间皮细胞粘附的影响。结果。新的人单克隆抗体 HMOCC-1 是一种识别卵巢上皮癌的免疫球蛋白 M。免疫组织化学染色显示 83.2% 的卵巢癌中 HMOCC-1 呈阳性。 HMOCC-1 识别的抗原显然是一种糖蛋白，因为蛋白质印迹产生了宽带 (34.8-49.1 kDa)。 HMOCC-1以浓度依赖性方式抑制RMG-I细胞与培养的腹膜间皮细胞单层的附着。结论。这种新的人类单克隆抗体与大多数测试的卵巢癌发生反应。 HMOCC-1识别的抗原是位于细胞膜上的糖蛋白。 HMOCC-1 对 RMG-I 细胞与间皮细胞附着的抑制表明该抗体在卵巢癌治疗中具有潜在作用。 (C) 2004 Elsevier Inc. 保留所有权利。
Objectives. Ovarian carcinoma is one of the most common gynecologic cancers and shows the worst prognosis since current therapies are not sufficiently effective at achieving and maintaining remission. To develop new treatment, a monoclonal antibody recognizing human ovarian cancer cells was raised in KM mice.Methods. A human monoclonal antibody targeting RMG-I (an ovarian carcinoma cell line) was established with hybridomas of myeloma cells and spleen cells from KM mice. The immunohistochemical reactivity of various types of ovarian carcinoma and other tumors was investigated. RMG-I cells were treated with N-glycosidase F, NaOH, H2SO4, and Gal NAC-alpha-benzyl to investigate the target antigens by Western blotting. The effect of HMOCC-1 on adhesion of RMG-I cells to cultured human mesothelial cells was also investigated.Results. The new human monoclonal antibody, HMOCC-1, was an immunoglobulin M that recognized ovarian epithelial carcinoma. Immunohistochemical staining revealed HMOCC-1 positivity in 83.2% of ovarian carcinomas. The antigen recognized by HMOCC-1 was apparently a glycoprotein since Western blotting yielded a broad band (34.8-49.1 kDa). HMOCC-1 inhibited the attachment of RMG-I cells to monolayers of cultured peritoneal mesothelial cells in a concentration-dependent manner.Conclusions. This new human monoclonal antibody reacted with most ovarian cancers tested. The antigen recognized by HMOCC-1 is a glycoprotein located on the cell membrane. Inhibition of the attachment of RMG-I cells to mesothelial cells by HMOCC-1 suggests a potential role for this antibody in the treatment of ovarian cancer. (C) 2004 Elsevier Inc. All rights reserved.